Skip to main content
. Author manuscript; available in PMC: 2015 Nov 18.
Published in final edited form as: Clin Cancer Res. 2011 Jul 8;17(21):6723–6732. doi: 10.1158/1078-0432.CCR-11-0770

Figure 4.

Figure 4

Pharmacologic inhibition of PDE4B improves GC sensitivity in B-cell lymphoma in vivo. Bioluminescent imaging of a cohort of 20 mice inoculated with Ramos cells stably expressing the luciferase gene. Images shown are from pretreatment (day 0–72 hours postinoculation) or at the 20th day of treatment with vehicle [1% DMSO in water, intraperitonealy (i.p.) daily], dexamethasone (15 mg/kg, i.p. daily), rolipram (10 mg/kg, i.p. daily), or the combination of both agents. The panel on the right is a photon flux–based quantification of tumor size and spread and confirms the statistically significant improvement in GC activity following its rational combination with a PDE4 inhibitor (*, P < 0.05, Kruskal–Wallis test). The combined analysis of 2 independent cohorts (n = 29) is shown in Supplementary Figure S3G.